Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;21(5):1368-1371.e2.
doi: 10.1016/j.cgh.2022.07.030. Epub 2022 Aug 6.

Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy

Affiliations

Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy

Fabienne Charbit-Henrion et al. Clin Gastroenterol Hepatol. 2023 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Representative endoscopic aspects in patients with CTLA4 variants and AIE. (1) Ulcerative gastritis with pseudobstruction in patient P9. (2) Duodenal villous atrophy in P1. (3) Colitis with ulcerations in P9. (B) Representative histologic lesions in patients with AIE. (1) Chronic fundic atrophic gastritis with intestinal metaplasia and focal low-grade dysplasia (×200) in P9 carrying a CTLA4 variant. (2) Chronic duodenitis in P1 with CTLA4 mutation with severe villous blunting and increased IEL numbers (×200). (3) Colitis with GVHD-like lesions and cryptic apoptotic bodies (×400) in a patient without identified pathogenic variant (description of numbered patients is provided in Supplementary Table 1). (C) Clinical features of the 48 patients with AIE. (D) Kaplan-Meier enteropathy-free survival curve of patients with (solid line) or without molecular diagnosis (dashed line). (E) Kaplan-Meier gastrointestinal malignant-free survival curve of patients with (solid line) or without molecular diagnosis (dashed line). (F) Number of patients for each individual molecular diagnosis. anti-TG2, antitransglutaminase of type 2; AI, autoimmune; AIE-75kDa, autoimmune enteropathy-related 75-kilodalton antibody; BMI, body mass index; C, colitis; IEL, intestinal intraepithelial hyperlymphocytosis; FLH, follicular lymphoid hyperplasia; G, gastritis; GI, gastrointestinal; GVHD, graft-versus-host disease; LPL, lamina propria hyperlymphocytosis; VA, villous atrophy.
Supplementary Figure 1
Supplementary Figure 1
Functional validation of novel mutations. (A): RT-PCR of STAT3-target SOCS3 at baseline and in IL-21 activated-EBV cell lines of P3 and P4. Results are shown as relative expression normalized to RPLPO housekeeping gene and represent the mean of 6 independent experiments. ∗P < .05, ∗∗P < .01, ∗∗∗P < ,005 Mann-Whitney test; HC: results pooled from 2 healthy controls (HC1 in green, HC2 in blue), PC: positive control; (B): Decreased CTLA-4 mean fluorescence intensity (MFI) on circulating T-cells in P1, P7 and P20 as compared to healthy control (HC) by flow cytometry; (C): B-cell immunophenotyping in P8, showing decreased frequency of CD27+ and excess of CD21lowCD38low B-cells.

Similar articles

Cited by

References

    1. Schiepatti A., et al. Gut. 2022 Jun 8 gutjnl-2021-326645.
    1. Villanacci V., et al. Clin Immunol. 2019;207:10–17. - PubMed
    1. Kobayashi I., et al. Gastroenterology. 1999;117:823–830. - PubMed
    1. Akram S., et al. Clin Gastroenterol Hepatol. 2007;5:1282–1290. quiz 1245. - PMC - PubMed
    1. Charbit-Henrion F., et al. Mucosal Immunol. 2021;14:1017–1037. - PubMed
Supplementary References
    1. Schubert D., et al. Nat Med. 2014;20:1410–1416. - PMC - PubMed
    1. Tuijnenburg P., et al. J Allergy Clin Immunol. 2018;142:1285–1296. - PMC - PubMed
    1. Fusaro M., et al. J Allergy Clin Immunol. 2021;147:734–737. - PubMed
    1. Arts P., et al. Genome Med. 2019;11:38. - PMC - PubMed
    1. Lee J.J., et al. J Allergy Clin Immunol. 2010;126:1234–1241. - PMC - PubMed

Publication types

Supplementary concepts